AustralieFrV1, PascalFrancis, Corpus, bibRecord, 004925

Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia : 3-year results from the EBMT randomized trial

Identifieur interne : 004925 ( PascalFrancis/Corpus ); précédent : 004924; suivant : 004926

Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia : 3-year results from the EBMT randomized trial

Auteurs : Norbert Schmitz ; Meral Beksac ; Andrea Bacigalupo ; Tapani Ruutu ; Arnon Nagler ; Eliane Gluckman ; Nigel Russell ; Jane Apperley ; Jeff Szer ; Kenneth Bradstock ; Agnes Buzyn ; Brigitte Schlegelberger ; James Matcham ; Alois Gratwohl

Source :

Haematologica : (Roma) [ 0390-6078 ] ; 2005.

RBID : Pascal:05-0272518

Descripteurs français

Pascal (Inist)
- Filgrastim, Mobilisation, Cellule hématopoïétique, Leucémie, Cellule souche, Etude comparative, Homogreffe, Moelle osseuse, Traitement, Essai clinique, Hématologie, EBMT.

English descriptors

KwdEn :
- Bone marrow, Clinical trial, Comparative study, European group for blood and marrow transplantation, Filgrastim, Hematology, Hematopoietic cell, Homograft, Leukemia, Mobilization, Stem cell, Treatment.

Abstract

Background and Objectives. Allogeneic peripheral blood progenitor cells (PBPC) are now widely used as the source of hematopoietic stem cells for transplantation. However, it is still not clear which patients should receive mobilized PBPC or bone marrow cells to reconstitute hematopoiesis after myeloablative conditioning. The aim of this study is to present 3-year-follow-up data on outcome (incidence and severity of chronic graft-versus-host disease (GVHD), overall survival (OS) and leukemia-free survival (LFS) after a PBPC transplant (PBPCT) or a bone marrow transplant (BMT). Design and Methods. Data on 350 patients with leukemia were collected in a multicenter, randomized study initiated by the EBMT. The patients were randomized to receive filgrastim-mobilized PBSCT or BMT from an HLA-identical donor. Results. At a median follow-up of 3 years, significantly more patients transplanted with PBPC than with bone marrow developed chronic GVHD (73% vs 55%, p=0.003) and extensive chronic GvHD (36% vs 19%, p=0.002). The higher incidence and greater severity of chronic GvHD had little impact on the patient's performance status or survival. OS was 58% for PBPCT recipients versus 65% among those undergoing BMT. LFS was 56% for PBPCT recipients versus 60% for BMT recipients. Interpretation and Conclusions. Patients transplanted with PBPC from an HLA-identical sibling develop more chronic GvHD than those transplanted with bone marrow, but the final impact of this difference is unclear. Longer follow-up is necessary to characterize the impact of chronic GvHD on quality of life, leukemia-free survival and overall survival.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0390-6078`
A03		`1`		`@0 Haematologica : (Roma)`
A05				`@2 90`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia : 3-year results from the EBMT randomized trial`
A11	`01`	`1`		`@1 SCHMITZ (Norbert)`
A11	`02`	`1`		`@1 BEKSAC (Meral)`
A11	`03`	`1`		`@1 BACIGALUPO (Andrea)`
A11	`04`	`1`		`@1 RUUTU (Tapani)`
A11	`05`	`1`		`@1 NAGLER (Arnon)`
A11	`06`	`1`		`@1 GLUCKMAN (Eliane)`
A11	`07`	`1`		`@1 RUSSELL (Nigel)`
A11	`08`	`1`		`@1 APPERLEY (Jane)`
A11	`09`	`1`		`@1 SZER (Jeff)`
A11	`10`	`1`		`@1 BRADSTOCK (Kenneth)`
A11	`11`	`1`		`@1 BUZYN (Agnes)`
A11	`12`	`1`		`@1 SCHLEGELBERGER (Brigitte)`
A11	`13`	`1`		`@1 MATCHAM (James)`
A11	`14`	`1`		`@1 GRATWOHL (Alois)`
A14	`01`			`@1 Dept. of Hematology, AK St. Georg @2 Hamburg @3 DEU @Z 1 aut.`
A14	`02`			`@1 Faculty of Medicine, Ankara University, Ibn-I Sina hospital @2 Ankara @3 TUR @Z 2 aut.`
A14	`03`			`@1 Dept. of Hematology, Ospedale San Martino @2 Genova @3 ITA @Z 3 aut.`
A14	`04`			`@1 Division of Hematology, Department of Medicine, Helsinki University Central Hospital @3 FIN @Z 4 aut.`
A14	`05`			`@1 Bone Marrow Transplantation Unit, Hadassah University Hospital @2 Jerusalem @3 ISR @Z 5 aut.`
A14	`06`			`@1 Bone Marrow Transplantation Unit, Hôpital Saint-Louis @2 Paris @3 FRA @Z 6 aut.`
A14	`07`			`@1 Dept. of Hematology, City Hospital @2 Nottingham @3 GBR @Z 7 aut.`
A14	`08`			`@1 Dept. of Hematology, Imperial College School of Medicine, Hammersmith Hospital @2 London @3 GBR @Z 8 aut.`
A14	`09`			`@1 Bone Marrow Transplant Service, The Royal Melbourne Hospital @2 Victoria @3 AUS @Z 9 aut.`
A14	`10`			`@1 Hematology Department, Institute of Clinical Pathology and Medical Research, Westmead Hospital @2 Sydney @3 AUS @Z 10 aut.`
A14	`11`			`@1 Hematology Dept., Hôpital Necker @2 Paris @3 FRA @Z 11 aut.`
A14	`12`			`@1 Institute for Cellular and Molecular Pathology, Hannover Medical School @2 Hannover @3 DEU @Z 12 aut.`
A14	`13`			`@1 Amgen Ltd @2 Cambridge @3 GBR @Z 13 aut.`
A14	`14`			`@1 Division of Hematology, Dep. Internal Medicine, Kantonsspital Basel @2 Basel @3 CHE @Z 14 aut.`
A20				`@1 643-648`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 3718 @5 354000124730630080`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 05-0272518`
A60				`@1 P @3 PR`
A61				`@0 A`
A64	`01`	`1`		`@0 Haematologica : (Roma)`
A66	`01`			`@0 ITA`
C01	`01`		`ENG`	@0 Background and Objectives. Allogeneic peripheral blood progenitor cells (PBPC) are now widely used as the source of hematopoietic stem cells for transplantation. However, it is still not clear which patients should receive mobilized PBPC or bone marrow cells to reconstitute hematopoiesis after myeloablative conditioning. The aim of this study is to present 3-year-follow-up data on outcome (incidence and severity of chronic graft-versus-host disease (GVHD), overall survival (OS) and leukemia-free survival (LFS) after a PBPC transplant (PBPCT) or a bone marrow transplant (BMT). Design and Methods. Data on 350 patients with leukemia were collected in a multicenter, randomized study initiated by the EBMT. The patients were randomized to receive filgrastim-mobilized PBSCT or BMT from an HLA-identical donor. Results. At a median follow-up of 3 years, significantly more patients transplanted with PBPC than with bone marrow developed chronic GVHD (73% vs 55%, p=0.003) and extensive chronic GvHD (36% vs 19%, p=0.002). The higher incidence and greater severity of chronic GvHD had little impact on the patient's performance status or survival. OS was 58% for PBPCT recipients versus 65% among those undergoing BMT. LFS was 56% for PBPCT recipients versus 60% for BMT recipients. Interpretation and Conclusions. Patients transplanted with PBPC from an HLA-identical sibling develop more chronic GvHD than those transplanted with bone marrow, but the final impact of this difference is unclear. Longer follow-up is necessary to characterize the impact of chronic GvHD on quality of life, leukemia-free survival and overall survival.
C02	`01`	`X`		`@0 002B19B`
C03	`01`	`X`	`FRE`	`@0 Filgrastim @2 NK @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Filgrastim @2 NK @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Filgrastim @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Mobilisation @5 02`
C03	`02`	`X`	`ENG`	`@0 Mobilization @5 02`
C03	`02`	`X`	`SPA`	`@0 Mobilización @5 02`
C03	`03`	`X`	`FRE`	`@0 Cellule hématopoïétique @5 03`
C03	`03`	`X`	`ENG`	`@0 Hematopoietic cell @5 03`
C03	`03`	`X`	`SPA`	`@0 Célula hematopoyética @5 03`
C03	`04`	`X`	`FRE`	`@0 Leucémie @5 04`
C03	`04`	`X`	`ENG`	`@0 Leukemia @5 04`
C03	`04`	`X`	`SPA`	`@0 Leucemia @5 04`
C03	`05`	`X`	`FRE`	`@0 Cellule souche @5 05`
C03	`05`	`X`	`ENG`	`@0 Stem cell @5 05`
C03	`05`	`X`	`SPA`	`@0 Célula primitiva @5 05`
C03	`06`	`X`	`FRE`	`@0 Etude comparative @5 06`
C03	`06`	`X`	`ENG`	`@0 Comparative study @5 06`
C03	`06`	`X`	`SPA`	`@0 Estudio comparativo @5 06`
C03	`07`	`X`	`FRE`	`@0 Homogreffe @5 07`
C03	`07`	`X`	`ENG`	`@0 Homograft @5 07`
C03	`07`	`X`	`SPA`	`@0 Homoinjerto @5 07`
C03	`08`	`X`	`FRE`	`@0 Moelle osseuse @5 08`
C03	`08`	`X`	`ENG`	`@0 Bone marrow @5 08`
C03	`08`	`X`	`SPA`	`@0 Médula ósea @5 08`
C03	`09`	`X`	`FRE`	`@0 Traitement @5 09`
C03	`09`	`X`	`ENG`	`@0 Treatment @5 09`
C03	`09`	`X`	`SPA`	`@0 Tratamiento @5 09`
C03	`10`	`X`	`FRE`	`@0 Essai clinique @5 11`
C03	`10`	`X`	`ENG`	`@0 Clinical trial @5 11`
C03	`10`	`X`	`SPA`	`@0 Ensayo clínico @5 11`
C03	`11`	`X`	`FRE`	`@0 Hématologie @5 12`
C03	`11`	`X`	`ENG`	`@0 Hematology @5 12`
C03	`11`	`X`	`SPA`	`@0 Hematología @5 12`
C03	`12`	`X`	`FRE`	`@0 EBMT @4 CD @5 96`
C03	`12`	`X`	`ENG`	`@0 European group for blood and marrow transplantation @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Cytokine @5 37`
C07	`01`	`X`	`ENG`	`@0 Cytokine @5 37`
C07	`01`	`X`	`SPA`	`@0 Citoquina @5 37`
C07	`02`	`X`	`FRE`	`@0 Facteur stimulant colonie granulocyte @5 38`
C07	`02`	`X`	`ENG`	`@0 Granulocyte colony stimulating factor @5 38`
C07	`02`	`X`	`SPA`	`@0 Factor estimulante colonia granulocito @5 38`
C07	`03`	`X`	`FRE`	`@0 Greffe @5 39`
C07	`03`	`X`	`ENG`	`@0 Graft @5 39`
C07	`03`	`X`	`SPA`	`@0 Injerto @5 39`
C07	`04`	`X`	`FRE`	`@0 Hémopathie maligne @5 40`
C07	`04`	`X`	`ENG`	`@0 Malignant hemopathy @5 40`
C07	`04`	`X`	`SPA`	`@0 Hemopatía maligna @5 40`
N21				`@1 192`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 05-0272518 INIST
ET :	Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia : 3-year results from the EBMT randomized trial
AU :	SCHMITZ (Norbert); BEKSAC (Meral); BACIGALUPO (Andrea); RUUTU (Tapani); NAGLER (Arnon); GLUCKMAN (Eliane); RUSSELL (Nigel); APPERLEY (Jane); SZER (Jeff); BRADSTOCK (Kenneth); BUZYN (Agnes); SCHLEGELBERGER (Brigitte); MATCHAM (James); GRATWOHL (Alois)
AF :	Dept. of Hematology, AK St. Georg/Hamburg/Allemagne (1 aut.); Faculty of Medicine, Ankara University, Ibn-I Sina hospital/Ankara/Turquie (2 aut.); Dept. of Hematology, Ospedale San Martino/Genova/Italie (3 aut.); Division of Hematology, Department of Medicine, Helsinki University Central Hospital/Finlande (4 aut.); Bone Marrow Transplantation Unit, Hadassah University Hospital/Jerusalem/Israël (5 aut.); Bone Marrow Transplantation Unit, Hôpital Saint-Louis/Paris/France (6 aut.); Dept. of Hematology, City Hospital/Nottingham/Royaume-Uni (7 aut.); Dept. of Hematology, Imperial College School of Medicine, Hammersmith Hospital/London/Royaume-Uni (8 aut.); Bone Marrow Transplant Service, The Royal Melbourne Hospital/Victoria/Australie (9 aut.); Hematology Department, Institute of Clinical Pathology and Medical Research, Westmead Hospital/Sydney/Australie (10 aut.); Hematology Dept., Hôpital Necker/Paris/France (11 aut.); Institute for Cellular and Molecular Pathology, Hannover Medical School/Hannover/Allemagne (12 aut.); Amgen Ltd/Cambridge/Royaume-Uni (13 aut.); Division of Hematology, Dep. Internal Medicine, Kantonsspital Basel/Basel/Suisse (14 aut.)
DT :	Publication en série; Papier de recherche; Niveau analytique
SO :	Haematologica : (Roma); ISSN 0390-6078; Italie; Da. 2005; Vol. 90; No. 5; Pp. 643-648; Bibl. 21 ref.
LA :	Anglais
EA :	Background and Objectives. Allogeneic peripheral blood progenitor cells (PBPC) are now widely used as the source of hematopoietic stem cells for transplantation. However, it is still not clear which patients should receive mobilized PBPC or bone marrow cells to reconstitute hematopoiesis after myeloablative conditioning. The aim of this study is to present 3-year-follow-up data on outcome (incidence and severity of chronic graft-versus-host disease (GVHD), overall survival (OS) and leukemia-free survival (LFS) after a PBPC transplant (PBPCT) or a bone marrow transplant (BMT). Design and Methods. Data on 350 patients with leukemia were collected in a multicenter, randomized study initiated by the EBMT. The patients were randomized to receive filgrastim-mobilized PBSCT or BMT from an HLA-identical donor. Results. At a median follow-up of 3 years, significantly more patients transplanted with PBPC than with bone marrow developed chronic GVHD (73% vs 55%, p=0.003) and extensive chronic GvHD (36% vs 19%, p=0.002). The higher incidence and greater severity of chronic GvHD had little impact on the patient's performance status or survival. OS was 58% for PBPCT recipients versus 65% among those undergoing BMT. LFS was 56% for PBPCT recipients versus 60% for BMT recipients. Interpretation and Conclusions. Patients transplanted with PBPC from an HLA-identical sibling develop more chronic GvHD than those transplanted with bone marrow, but the final impact of this difference is unclear. Longer follow-up is necessary to characterize the impact of chronic GvHD on quality of life, leukemia-free survival and overall survival.
CC :	002B19B
FD :	Filgrastim; Mobilisation; Cellule hématopoïétique; Leucémie; Cellule souche; Etude comparative; Homogreffe; Moelle osseuse; Traitement; Essai clinique; Hématologie; EBMT
FG :	Cytokine; Facteur stimulant colonie granulocyte; Greffe; Hémopathie maligne
ED :	Filgrastim; Mobilization; Hematopoietic cell; Leukemia; Stem cell; Comparative study; Homograft; Bone marrow; Treatment; Clinical trial; Hematology; European group for blood and marrow transplantation
EG :	Cytokine; Granulocyte colony stimulating factor; Graft; Malignant hemopathy
SD :	Filgrastim; Mobilización; Célula hematopoyética; Leucemia; Célula primitiva; Estudio comparativo; Homoinjerto; Médula ósea; Tratamiento; Ensayo clínico; Hematología
LO :	INIST-3718.354000124730630080
ID :	05-0272518

Links to Exploration step

Pascal:05-0272518

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia : 3-year results from the EBMT randomized trial</title>
<author><name sortKey="Schmitz, Norbert" sort="Schmitz, Norbert" uniqKey="Schmitz N" first="Norbert" last="Schmitz">Norbert Schmitz</name>
<affiliation><inist:fA14 i1="01"><s1>Dept. of Hematology, AK St. Georg</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Beksac, Meral" sort="Beksac, Meral" uniqKey="Beksac M" first="Meral" last="Beksac">Meral Beksac</name>
<affiliation><inist:fA14 i1="02"><s1>Faculty of Medicine, Ankara University, Ibn-I Sina hospital</s1>
<s2>Ankara</s2>
<s3>TUR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bacigalupo, Andrea" sort="Bacigalupo, Andrea" uniqKey="Bacigalupo A" first="Andrea" last="Bacigalupo">Andrea Bacigalupo</name>
<affiliation><inist:fA14 i1="03"><s1>Dept. of Hematology, Ospedale San Martino</s1>
<s2>Genova</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ruutu, Tapani" sort="Ruutu, Tapani" uniqKey="Ruutu T" first="Tapani" last="Ruutu">Tapani Ruutu</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Hematology, Department of Medicine, Helsinki University Central Hospital</s1>
<s3>FIN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nagler, Arnon" sort="Nagler, Arnon" uniqKey="Nagler A" first="Arnon" last="Nagler">Arnon Nagler</name>
<affiliation><inist:fA14 i1="05"><s1>Bone Marrow Transplantation Unit, Hadassah University Hospital</s1>
<s2>Jerusalem</s2>
<s3>ISR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gluckman, Eliane" sort="Gluckman, Eliane" uniqKey="Gluckman E" first="Eliane" last="Gluckman">Eliane Gluckman</name>
<affiliation><inist:fA14 i1="06"><s1>Bone Marrow Transplantation Unit, Hôpital Saint-Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Russell, Nigel" sort="Russell, Nigel" uniqKey="Russell N" first="Nigel" last="Russell">Nigel Russell</name>
<affiliation><inist:fA14 i1="07"><s1>Dept. of Hematology, City Hospital</s1>
<s2>Nottingham</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Apperley, Jane" sort="Apperley, Jane" uniqKey="Apperley J" first="Jane" last="Apperley">Jane Apperley</name>
<affiliation><inist:fA14 i1="08"><s1>Dept. of Hematology, Imperial College School of Medicine, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Szer, Jeff" sort="Szer, Jeff" uniqKey="Szer J" first="Jeff" last="Szer">Jeff Szer</name>
<affiliation><inist:fA14 i1="09"><s1>Bone Marrow Transplant Service, The Royal Melbourne Hospital</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bradstock, Kenneth" sort="Bradstock, Kenneth" uniqKey="Bradstock K" first="Kenneth" last="Bradstock">Kenneth Bradstock</name>
<affiliation><inist:fA14 i1="10"><s1>Hematology Department, Institute of Clinical Pathology and Medical Research, Westmead Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Buzyn, Agnes" sort="Buzyn, Agnes" uniqKey="Buzyn A" first="Agnes" last="Buzyn">Agnes Buzyn</name>
<affiliation><inist:fA14 i1="11"><s1>Hematology Dept., Hôpital Necker</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schlegelberger, Brigitte" sort="Schlegelberger, Brigitte" uniqKey="Schlegelberger B" first="Brigitte" last="Schlegelberger">Brigitte Schlegelberger</name>
<affiliation><inist:fA14 i1="12"><s1>Institute for Cellular and Molecular Pathology, Hannover Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Matcham, James" sort="Matcham, James" uniqKey="Matcham J" first="James" last="Matcham">James Matcham</name>
<affiliation><inist:fA14 i1="13"><s1>Amgen Ltd</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gratwohl, Alois" sort="Gratwohl, Alois" uniqKey="Gratwohl A" first="Alois" last="Gratwohl">Alois Gratwohl</name>
<affiliation><inist:fA14 i1="14"><s1>Division of Hematology, Dep. Internal Medicine, Kantonsspital Basel</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0272518</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0272518 INIST</idno>
<idno type="RBID">Pascal:05-0272518</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">004925</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia : 3-year results from the EBMT randomized trial</title>
<author><name sortKey="Schmitz, Norbert" sort="Schmitz, Norbert" uniqKey="Schmitz N" first="Norbert" last="Schmitz">Norbert Schmitz</name>
<affiliation><inist:fA14 i1="01"><s1>Dept. of Hematology, AK St. Georg</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Beksac, Meral" sort="Beksac, Meral" uniqKey="Beksac M" first="Meral" last="Beksac">Meral Beksac</name>
<affiliation><inist:fA14 i1="02"><s1>Faculty of Medicine, Ankara University, Ibn-I Sina hospital</s1>
<s2>Ankara</s2>
<s3>TUR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bacigalupo, Andrea" sort="Bacigalupo, Andrea" uniqKey="Bacigalupo A" first="Andrea" last="Bacigalupo">Andrea Bacigalupo</name>
<affiliation><inist:fA14 i1="03"><s1>Dept. of Hematology, Ospedale San Martino</s1>
<s2>Genova</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ruutu, Tapani" sort="Ruutu, Tapani" uniqKey="Ruutu T" first="Tapani" last="Ruutu">Tapani Ruutu</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Hematology, Department of Medicine, Helsinki University Central Hospital</s1>
<s3>FIN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nagler, Arnon" sort="Nagler, Arnon" uniqKey="Nagler A" first="Arnon" last="Nagler">Arnon Nagler</name>
<affiliation><inist:fA14 i1="05"><s1>Bone Marrow Transplantation Unit, Hadassah University Hospital</s1>
<s2>Jerusalem</s2>
<s3>ISR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gluckman, Eliane" sort="Gluckman, Eliane" uniqKey="Gluckman E" first="Eliane" last="Gluckman">Eliane Gluckman</name>
<affiliation><inist:fA14 i1="06"><s1>Bone Marrow Transplantation Unit, Hôpital Saint-Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Russell, Nigel" sort="Russell, Nigel" uniqKey="Russell N" first="Nigel" last="Russell">Nigel Russell</name>
<affiliation><inist:fA14 i1="07"><s1>Dept. of Hematology, City Hospital</s1>
<s2>Nottingham</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Apperley, Jane" sort="Apperley, Jane" uniqKey="Apperley J" first="Jane" last="Apperley">Jane Apperley</name>
<affiliation><inist:fA14 i1="08"><s1>Dept. of Hematology, Imperial College School of Medicine, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Szer, Jeff" sort="Szer, Jeff" uniqKey="Szer J" first="Jeff" last="Szer">Jeff Szer</name>
<affiliation><inist:fA14 i1="09"><s1>Bone Marrow Transplant Service, The Royal Melbourne Hospital</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bradstock, Kenneth" sort="Bradstock, Kenneth" uniqKey="Bradstock K" first="Kenneth" last="Bradstock">Kenneth Bradstock</name>
<affiliation><inist:fA14 i1="10"><s1>Hematology Department, Institute of Clinical Pathology and Medical Research, Westmead Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Buzyn, Agnes" sort="Buzyn, Agnes" uniqKey="Buzyn A" first="Agnes" last="Buzyn">Agnes Buzyn</name>
<affiliation><inist:fA14 i1="11"><s1>Hematology Dept., Hôpital Necker</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schlegelberger, Brigitte" sort="Schlegelberger, Brigitte" uniqKey="Schlegelberger B" first="Brigitte" last="Schlegelberger">Brigitte Schlegelberger</name>
<affiliation><inist:fA14 i1="12"><s1>Institute for Cellular and Molecular Pathology, Hannover Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Matcham, James" sort="Matcham, James" uniqKey="Matcham J" first="James" last="Matcham">James Matcham</name>
<affiliation><inist:fA14 i1="13"><s1>Amgen Ltd</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gratwohl, Alois" sort="Gratwohl, Alois" uniqKey="Gratwohl A" first="Alois" last="Gratwohl">Alois Gratwohl</name>
<affiliation><inist:fA14 i1="14"><s1>Division of Hematology, Dep. Internal Medicine, Kantonsspital Basel</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Haematologica : (Roma)</title>
<title level="j" type="abbreviated">Haematologica : (Roma)</title>
<idno type="ISSN">0390-6078</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Haematologica : (Roma)</title>
<title level="j" type="abbreviated">Haematologica : (Roma)</title>
<idno type="ISSN">0390-6078</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bone marrow</term>
<term>Clinical trial</term>
<term>Comparative study</term>
<term>European group for blood and marrow transplantation</term>
<term>Filgrastim</term>
<term>Hematology</term>
<term>Hematopoietic cell</term>
<term>Homograft</term>
<term>Leukemia</term>
<term>Mobilization</term>
<term>Stem cell</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Filgrastim</term>
<term>Mobilisation</term>
<term>Cellule hématopoïétique</term>
<term>Leucémie</term>
<term>Cellule souche</term>
<term>Etude comparative</term>
<term>Homogreffe</term>
<term>Moelle osseuse</term>
<term>Traitement</term>
<term>Essai clinique</term>
<term>Hématologie</term>
<term>EBMT</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background and Objectives. Allogeneic peripheral blood progenitor cells (PBPC) are now widely used as the source of hematopoietic stem cells for transplantation. However, it is still not clear which patients should receive mobilized PBPC or bone marrow cells to reconstitute hematopoiesis after myeloablative conditioning. The aim of this study is to present 3-year-follow-up data on outcome (incidence and severity of chronic graft-versus-host disease (GVHD), overall survival (OS) and leukemia-free survival (LFS) after a PBPC transplant (PBPCT) or a bone marrow transplant (BMT). Design and Methods. Data on 350 patients with leukemia were collected in a multicenter, randomized study initiated by the EBMT. The patients were randomized to receive filgrastim-mobilized PBSCT or BMT from an HLA-identical donor. Results. At a median follow-up of 3 years, significantly more patients transplanted with PBPC than with bone marrow developed chronic GVHD (73% vs 55%, p=0.003) and extensive chronic GvHD (36% vs 19%, p=0.002). The higher incidence and greater severity of chronic GvHD had little impact on the patient's performance status or survival. OS was 58% for PBPCT recipients versus 65% among those undergoing BMT. LFS was 56% for PBPCT recipients versus 60% for BMT recipients. Interpretation and Conclusions. Patients transplanted with PBPC from an HLA-identical sibling develop more chronic GvHD than those transplanted with bone marrow, but the final impact of this difference is unclear. Longer follow-up is necessary to characterize the impact of chronic GvHD on quality of life, leukemia-free survival and overall survival.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0390-6078</s0>
</fA01>
<fA03 i2="1"><s0>Haematologica : (Roma)</s0>
</fA03>
<fA05><s2>90</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia : 3-year results from the EBMT randomized trial</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SCHMITZ (Norbert)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BEKSAC (Meral)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BACIGALUPO (Andrea)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>RUUTU (Tapani)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>NAGLER (Arnon)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GLUCKMAN (Eliane)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>RUSSELL (Nigel)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>APPERLEY (Jane)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>SZER (Jeff)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>BRADSTOCK (Kenneth)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>BUZYN (Agnes)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>SCHLEGELBERGER (Brigitte)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>MATCHAM (James)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>GRATWOHL (Alois)</s1>
</fA11>
<fA14 i1="01"><s1>Dept. of Hematology, AK St. Georg</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Faculty of Medicine, Ankara University, Ibn-I Sina hospital</s1>
<s2>Ankara</s2>
<s3>TUR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Dept. of Hematology, Ospedale San Martino</s1>
<s2>Genova</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Division of Hematology, Department of Medicine, Helsinki University Central Hospital</s1>
<s3>FIN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Bone Marrow Transplantation Unit, Hadassah University Hospital</s1>
<s2>Jerusalem</s2>
<s3>ISR</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Bone Marrow Transplantation Unit, Hôpital Saint-Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Dept. of Hematology, City Hospital</s1>
<s2>Nottingham</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Dept. of Hematology, Imperial College School of Medicine, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Bone Marrow Transplant Service, The Royal Melbourne Hospital</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Hematology Department, Institute of Clinical Pathology and Medical Research, Westmead Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Hematology Dept., Hôpital Necker</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Institute for Cellular and Molecular Pathology, Hannover Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Amgen Ltd</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Division of Hematology, Dep. Internal Medicine, Kantonsspital Basel</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA20><s1>643-648</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>3718</s2>
<s5>354000124730630080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0272518</s0>
</fA47>
<fA60><s1>P</s1>
<s3>PR</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Haematologica : (Roma)</s0>
</fA64>
<fA66 i1="01"><s0>ITA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background and Objectives. Allogeneic peripheral blood progenitor cells (PBPC) are now widely used as the source of hematopoietic stem cells for transplantation. However, it is still not clear which patients should receive mobilized PBPC or bone marrow cells to reconstitute hematopoiesis after myeloablative conditioning. The aim of this study is to present 3-year-follow-up data on outcome (incidence and severity of chronic graft-versus-host disease (GVHD), overall survival (OS) and leukemia-free survival (LFS) after a PBPC transplant (PBPCT) or a bone marrow transplant (BMT). Design and Methods. Data on 350 patients with leukemia were collected in a multicenter, randomized study initiated by the EBMT. The patients were randomized to receive filgrastim-mobilized PBSCT or BMT from an HLA-identical donor. Results. At a median follow-up of 3 years, significantly more patients transplanted with PBPC than with bone marrow developed chronic GVHD (73% vs 55%, p=0.003) and extensive chronic GvHD (36% vs 19%, p=0.002). The higher incidence and greater severity of chronic GvHD had little impact on the patient's performance status or survival. OS was 58% for PBPCT recipients versus 65% among those undergoing BMT. LFS was 56% for PBPCT recipients versus 60% for BMT recipients. Interpretation and Conclusions. Patients transplanted with PBPC from an HLA-identical sibling develop more chronic GvHD than those transplanted with bone marrow, but the final impact of this difference is unclear. Longer follow-up is necessary to characterize the impact of chronic GvHD on quality of life, leukemia-free survival and overall survival.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B19B</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Filgrastim</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Filgrastim</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Filgrastim</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Mobilisation</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Mobilization</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Mobilización</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Cellule hématopoïétique</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Hematopoietic cell</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Célula hematopoyética</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Leucémie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Leukemia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Leucemia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Cellule souche</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Stem cell</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Célula primitiva</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homogreffe</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Homograft</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Homoinjerto</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Moelle osseuse</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Bone marrow</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Médula ósea</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Hématologie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Hematology</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Hematología</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>EBMT</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>European group for blood and marrow transplantation</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Cytokine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cytokine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Citoquina</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Facteur stimulant colonie granulocyte</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Granulocyte colony stimulating factor</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Factor estimulante colonia granulocito</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Greffe</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Graft</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Injerto</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Hémopathie maligne</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Malignant hemopathy</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Hemopatía maligna</s0>
<s5>40</s5>
</fC07>
<fN21><s1>192</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 05-0272518 INIST</NO>
<ET>Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia : 3-year results from the EBMT randomized trial</ET>
<AU>SCHMITZ (Norbert); BEKSAC (Meral); BACIGALUPO (Andrea); RUUTU (Tapani); NAGLER (Arnon); GLUCKMAN (Eliane); RUSSELL (Nigel); APPERLEY (Jane); SZER (Jeff); BRADSTOCK (Kenneth); BUZYN (Agnes); SCHLEGELBERGER (Brigitte); MATCHAM (James); GRATWOHL (Alois)</AU>
<AF>Dept. of Hematology, AK St. Georg/Hamburg/Allemagne (1 aut.); Faculty of Medicine, Ankara University, Ibn-I Sina hospital/Ankara/Turquie (2 aut.); Dept. of Hematology, Ospedale San Martino/Genova/Italie (3 aut.); Division of Hematology, Department of Medicine, Helsinki University Central Hospital/Finlande (4 aut.); Bone Marrow Transplantation Unit, Hadassah University Hospital/Jerusalem/Israël (5 aut.); Bone Marrow Transplantation Unit, Hôpital Saint-Louis/Paris/France (6 aut.); Dept. of Hematology, City Hospital/Nottingham/Royaume-Uni (7 aut.); Dept. of Hematology, Imperial College School of Medicine, Hammersmith Hospital/London/Royaume-Uni (8 aut.); Bone Marrow Transplant Service, The Royal Melbourne Hospital/Victoria/Australie (9 aut.); Hematology Department, Institute of Clinical Pathology and Medical Research, Westmead Hospital/Sydney/Australie (10 aut.); Hematology Dept., Hôpital Necker/Paris/France (11 aut.); Institute for Cellular and Molecular Pathology, Hannover Medical School/Hannover/Allemagne (12 aut.); Amgen Ltd/Cambridge/Royaume-Uni (13 aut.); Division of Hematology, Dep. Internal Medicine, Kantonsspital Basel/Basel/Suisse (14 aut.)</AF>
<DT>Publication en série; Papier de recherche; Niveau analytique</DT>
<SO>Haematologica : (Roma); ISSN 0390-6078; Italie; Da. 2005; Vol. 90; No. 5; Pp. 643-648; Bibl. 21 ref.</SO>
<LA>Anglais</LA>
<EA>Background and Objectives. Allogeneic peripheral blood progenitor cells (PBPC) are now widely used as the source of hematopoietic stem cells for transplantation. However, it is still not clear which patients should receive mobilized PBPC or bone marrow cells to reconstitute hematopoiesis after myeloablative conditioning. The aim of this study is to present 3-year-follow-up data on outcome (incidence and severity of chronic graft-versus-host disease (GVHD), overall survival (OS) and leukemia-free survival (LFS) after a PBPC transplant (PBPCT) or a bone marrow transplant (BMT). Design and Methods. Data on 350 patients with leukemia were collected in a multicenter, randomized study initiated by the EBMT. The patients were randomized to receive filgrastim-mobilized PBSCT or BMT from an HLA-identical donor. Results. At a median follow-up of 3 years, significantly more patients transplanted with PBPC than with bone marrow developed chronic GVHD (73% vs 55%, p=0.003) and extensive chronic GvHD (36% vs 19%, p=0.002). The higher incidence and greater severity of chronic GvHD had little impact on the patient's performance status or survival. OS was 58% for PBPCT recipients versus 65% among those undergoing BMT. LFS was 56% for PBPCT recipients versus 60% for BMT recipients. Interpretation and Conclusions. Patients transplanted with PBPC from an HLA-identical sibling develop more chronic GvHD than those transplanted with bone marrow, but the final impact of this difference is unclear. Longer follow-up is necessary to characterize the impact of chronic GvHD on quality of life, leukemia-free survival and overall survival.</EA>
<CC>002B19B</CC>
<FD>Filgrastim; Mobilisation; Cellule hématopoïétique; Leucémie; Cellule souche; Etude comparative; Homogreffe; Moelle osseuse; Traitement; Essai clinique; Hématologie; EBMT</FD>
<FG>Cytokine; Facteur stimulant colonie granulocyte; Greffe; Hémopathie maligne</FG>
<ED>Filgrastim; Mobilization; Hematopoietic cell; Leukemia; Stem cell; Comparative study; Homograft; Bone marrow; Treatment; Clinical trial; Hematology; European group for blood and marrow transplantation</ED>
<EG>Cytokine; Granulocyte colony stimulating factor; Graft; Malignant hemopathy</EG>
<SD>Filgrastim; Mobilización; Célula hematopoyética; Leucemia; Célula primitiva; Estudio comparativo; Homoinjerto; Médula ósea; Tratamiento; Ensayo clínico; Hematología</SD>
<LO>INIST-3718.354000124730630080</LO>
<ID>05-0272518</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004925 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 004925 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0272518
   |texte=   Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia : 3-year results from the EBMT randomized trial
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia : 3-year results from the EBMT randomized trial

Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia : 3-year results from the EBMT randomized trial

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri